Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

The various surgical and radiologic methods of treating acromegaly have dramatically improved over the past 75 years. In addition to the improvements in primary surgical and radiation methods ...

"One in two million" – George Moanaroa was diagnosed with acromegaly in 2022 and hopes to educate whānau on the rare condition. Photo / Te Ao Māori News George Moanaroa believes the spiritual ...

JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential.

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

Under the patronage of His Highness Sheikh Mohamed Bin Zayed Al Nahyan, President of the UAE, the Abu Dhabi Arabic Language ...

KLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC.

Her leadership for the past 2.5 years has been polarizing, and led to controversies both internal and external.